JP2018518974A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018518974A5 JP2018518974A5 JP2017567178A JP2017567178A JP2018518974A5 JP 2018518974 A5 JP2018518974 A5 JP 2018518974A5 JP 2017567178 A JP2017567178 A JP 2017567178A JP 2017567178 A JP2017567178 A JP 2017567178A JP 2018518974 A5 JP2018518974 A5 JP 2018518974A5
- Authority
- JP
- Japan
- Prior art keywords
- domain
- antigen recognition
- receptor
- cells
- antigen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000427 antigen Substances 0.000 claims 32
- 102000036639 antigens Human genes 0.000 claims 32
- 108091007433 antigens Proteins 0.000 claims 32
- 102100033726 Tumor necrosis factor receptor superfamily member 17 Human genes 0.000 claims 21
- 102000004196 processed proteins & peptides Human genes 0.000 claims 20
- 108090000765 processed proteins & peptides Proteins 0.000 claims 20
- 210000004027 cell Anatomy 0.000 claims 19
- 229920001184 polypeptide Polymers 0.000 claims 19
- 101000795167 Homo sapiens Tumor necrosis factor receptor superfamily member 13B Proteins 0.000 claims 17
- 102100029675 Tumor necrosis factor receptor superfamily member 13B Human genes 0.000 claims 17
- 101000801255 Homo sapiens Tumor necrosis factor receptor superfamily member 17 Proteins 0.000 claims 14
- 102100038080 B-cell receptor CD22 Human genes 0.000 claims 13
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 claims 13
- 101000884305 Homo sapiens B-cell receptor CD22 Proteins 0.000 claims 13
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 claims 13
- 102100031585 ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Human genes 0.000 claims 12
- 102000010956 Glypican Human genes 0.000 claims 12
- 108050001154 Glypican Proteins 0.000 claims 12
- 108050007237 Glypican-3 Proteins 0.000 claims 12
- 101000777636 Homo sapiens ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Proteins 0.000 claims 12
- 101000874179 Homo sapiens Syndecan-1 Proteins 0.000 claims 12
- -1 LeY Proteins 0.000 claims 12
- 102100035721 Syndecan-1 Human genes 0.000 claims 12
- 102000013529 alpha-Fetoproteins Human genes 0.000 claims 12
- 108010026331 alpha-Fetoproteins Proteins 0.000 claims 12
- 230000000139 costimulatory effect Effects 0.000 claims 12
- 238000000034 method Methods 0.000 claims 12
- 101000998120 Homo sapiens Interleukin-3 receptor subunit alpha Proteins 0.000 claims 11
- 101000934338 Homo sapiens Myeloid cell surface antigen CD33 Proteins 0.000 claims 11
- 102100033493 Interleukin-3 receptor subunit alpha Human genes 0.000 claims 11
- 102100025243 Myeloid cell surface antigen CD33 Human genes 0.000 claims 11
- 101001005269 Arabidopsis thaliana Ceramide synthase 1 LOH3 Proteins 0.000 claims 10
- 101001005312 Arabidopsis thaliana Ceramide synthase LOH1 Proteins 0.000 claims 10
- 102100022005 B-lymphocyte antigen CD20 Human genes 0.000 claims 10
- 102100028801 Calsyntenin-1 Human genes 0.000 claims 10
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 claims 10
- 101000897405 Homo sapiens B-lymphocyte antigen CD20 Proteins 0.000 claims 10
- 101000633784 Homo sapiens SLAM family member 7 Proteins 0.000 claims 10
- 101000668858 Spinacia oleracea 30S ribosomal protein S1, chloroplastic Proteins 0.000 claims 10
- 101000898746 Streptomyces clavuligerus Clavaminate synthase 1 Proteins 0.000 claims 10
- 102100025244 T-cell surface glycoprotein CD5 Human genes 0.000 claims 10
- BGFTWECWAICPDG-UHFFFAOYSA-N 2-[bis(4-chlorophenyl)methyl]-4-n-[3-[bis(4-chlorophenyl)methyl]-4-(dimethylamino)phenyl]-1-n,1-n-dimethylbenzene-1,4-diamine Chemical compound C1=C(C(C=2C=CC(Cl)=CC=2)C=2C=CC(Cl)=CC=2)C(N(C)C)=CC=C1NC(C=1)=CC=C(N(C)C)C=1C(C=1C=CC(Cl)=CC=1)C1=CC=C(Cl)C=C1 BGFTWECWAICPDG-UHFFFAOYSA-N 0.000 claims 7
- 108010008014 B-Cell Maturation Antigen Proteins 0.000 claims 7
- 102100035248 Alpha-(1,3)-fucosyltransferase 4 Human genes 0.000 claims 6
- 102100022749 Aminopeptidase N Human genes 0.000 claims 6
- 102100025570 Cancer/testis antigen 1 Human genes 0.000 claims 6
- 102100026122 High affinity immunoglobulin gamma Fc receptor I Human genes 0.000 claims 6
- 101001022185 Homo sapiens Alpha-(1,3)-fucosyltransferase 4 Proteins 0.000 claims 6
- 101000757160 Homo sapiens Aminopeptidase N Proteins 0.000 claims 6
- 101000856237 Homo sapiens Cancer/testis antigen 1 Proteins 0.000 claims 6
- 101000913074 Homo sapiens High affinity immunoglobulin gamma Fc receptor I Proteins 0.000 claims 6
- 101001078143 Homo sapiens Integrin alpha-IIb Proteins 0.000 claims 6
- 101001015004 Homo sapiens Integrin beta-3 Proteins 0.000 claims 6
- 101000934372 Homo sapiens Macrosialin Proteins 0.000 claims 6
- 101001008874 Homo sapiens Mast/stem cell growth factor receptor Kit Proteins 0.000 claims 6
- 101000946889 Homo sapiens Monocyte differentiation antigen CD14 Proteins 0.000 claims 6
- 101000934341 Homo sapiens T-cell surface glycoprotein CD5 Proteins 0.000 claims 6
- 102100025306 Integrin alpha-IIb Human genes 0.000 claims 6
- 102100032999 Integrin beta-3 Human genes 0.000 claims 6
- 108010038501 Interleukin-6 Receptors Proteins 0.000 claims 6
- 102100037792 Interleukin-6 receptor subunit alpha Human genes 0.000 claims 6
- 102100025136 Macrosialin Human genes 0.000 claims 6
- 102100027754 Mast/stem cell growth factor receptor Kit Human genes 0.000 claims 6
- 102100035877 Monocyte differentiation antigen CD14 Human genes 0.000 claims 6
- 101100335081 Mus musculus Flt3 gene Proteins 0.000 claims 6
- 108010076504 Protein Sorting Signals Proteins 0.000 claims 6
- 210000001744 T-lymphocyte Anatomy 0.000 claims 6
- 102100029690 Tumor necrosis factor receptor superfamily member 13C Human genes 0.000 claims 6
- 101710178300 Tumor necrosis factor receptor superfamily member 13C Proteins 0.000 claims 6
- 230000011664 signaling Effects 0.000 claims 6
- 102100036011 T-cell surface glycoprotein CD4 Human genes 0.000 claims 5
- 102100034922 T-cell surface glycoprotein CD8 alpha chain Human genes 0.000 claims 5
- 239000012634 fragment Substances 0.000 claims 4
- 102000005962 receptors Human genes 0.000 claims 4
- 108020003175 receptors Proteins 0.000 claims 4
- 102100023990 60S ribosomal protein L17 Human genes 0.000 claims 3
- 108010074708 B7-H1 Antigen Proteins 0.000 claims 3
- 102100024217 CAMPATH-1 antigen Human genes 0.000 claims 3
- 102000017420 CD3 protein, epsilon/gamma/delta subunit Human genes 0.000 claims 3
- 108010065524 CD52 Antigen Proteins 0.000 claims 3
- 102100034458 Hepatitis A virus cellular receptor 2 Human genes 0.000 claims 3
- 101710083479 Hepatitis A virus cellular receptor 2 homolog Proteins 0.000 claims 3
- 101000916644 Homo sapiens Macrophage colony-stimulating factor 1 receptor Proteins 0.000 claims 3
- 108010065805 Interleukin-12 Proteins 0.000 claims 3
- 108090000172 Interleukin-15 Proteins 0.000 claims 3
- 102100020789 Interleukin-15 receptor subunit alpha Human genes 0.000 claims 3
- 101710107699 Interleukin-15 receptor subunit alpha Proteins 0.000 claims 3
- 108010002350 Interleukin-2 Proteins 0.000 claims 3
- 108010002586 Interleukin-7 Proteins 0.000 claims 3
- 102100028198 Macrophage colony-stimulating factor 1 receptor Human genes 0.000 claims 3
- 102100024216 Programmed cell death 1 ligand 1 Human genes 0.000 claims 3
- 101710089372 Programmed cell death protein 1 Proteins 0.000 claims 3
- 229940126547 T-cell immunoglobulin mucin-3 Drugs 0.000 claims 3
- 102100025237 T-cell surface antigen CD2 Human genes 0.000 claims 3
- 239000003623 enhancer Substances 0.000 claims 3
- 108010074108 interleukin-21 Proteins 0.000 claims 3
- 108010083359 Antigen Receptors Proteins 0.000 claims 2
- 102000006306 Antigen Receptors Human genes 0.000 claims 2
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 claims 2
- 208000034578 Multiple myelomas Diseases 0.000 claims 2
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 2
- 102100027208 T-cell antigen CD7 Human genes 0.000 claims 2
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 claims 2
- 238000003776 cleavage reaction Methods 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 210000000581 natural killer T-cell Anatomy 0.000 claims 2
- 210000000822 natural killer cell Anatomy 0.000 claims 2
- 230000002062 proliferating effect Effects 0.000 claims 2
- 230000007017 scission Effects 0.000 claims 2
- 101000738771 Homo sapiens Receptor-type tyrosine-protein phosphatase C Proteins 0.000 claims 1
- 206010020631 Hypergammaglobulinaemia benign monoclonal Diseases 0.000 claims 1
- 208000001715 Osteoblastoma Diseases 0.000 claims 1
- 208000002774 Paraproteinemias Diseases 0.000 claims 1
- 208000007452 Plasmacytoma Diseases 0.000 claims 1
- 102100037422 Receptor-type tyrosine-protein phosphatase C Human genes 0.000 claims 1
- 125000003275 alpha amino acid group Chemical group 0.000 claims 1
- 206010002022 amyloidosis Diseases 0.000 claims 1
- 208000025750 heavy chain disease Diseases 0.000 claims 1
- 201000005328 monoclonal gammopathy of uncertain significance Diseases 0.000 claims 1
- 208000031223 plasma cell leukemia Diseases 0.000 claims 1
Priority Applications (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021167360A JP7254870B2 (ja) | 2015-06-25 | 2021-10-12 | キメラ抗体受容体（ＣＡＲｓ）の構成およびその使用方法 |
| JP2023053851A JP7502515B2 (ja) | 2015-06-25 | 2023-03-29 | キメラ抗体受容体（ＣＡＲｓ）の構成およびその使用方法 |
| JP2024092213A JP2024116259A (ja) | 2015-06-25 | 2024-06-06 | キメラ抗体受容体（ＣＡＲｓ）の構成およびその使用方法 |
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562184321P | 2015-06-25 | 2015-06-25 | |
| US62/184,321 | 2015-06-25 | ||
| US201562235840P | 2015-10-01 | 2015-10-01 | |
| US62/235,840 | 2015-10-01 | ||
| US201562244435P | 2015-10-21 | 2015-10-21 | |
| US62/244,435 | 2015-10-21 | ||
| PCT/US2016/039306 WO2016210293A1 (en) | 2015-06-25 | 2016-06-24 | CHIMERIC ANTIGEN RECEPTORS (CARs), COMPOSITIONS AND METHODS OF USE THEREOF |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021167360A Division JP7254870B2 (ja) | 2015-06-25 | 2021-10-12 | キメラ抗体受容体（ＣＡＲｓ）の構成およびその使用方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018518974A JP2018518974A (ja) | 2018-07-19 |
| JP2018518974A5 true JP2018518974A5 (https=) | 2019-07-18 |
| JP6961497B2 JP6961497B2 (ja) | 2021-11-05 |
Family
ID=57586695
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017567178A Active JP6961497B2 (ja) | 2015-06-25 | 2016-06-24 | キメラ抗体受容体（ＣＡＲｓ）の構成およびその使用方法 |
| JP2021167360A Active JP7254870B2 (ja) | 2015-06-25 | 2021-10-12 | キメラ抗体受容体（ＣＡＲｓ）の構成およびその使用方法 |
| JP2023053851A Active JP7502515B2 (ja) | 2015-06-25 | 2023-03-29 | キメラ抗体受容体（ＣＡＲｓ）の構成およびその使用方法 |
| JP2024092213A Pending JP2024116259A (ja) | 2015-06-25 | 2024-06-06 | キメラ抗体受容体（ＣＡＲｓ）の構成およびその使用方法 |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021167360A Active JP7254870B2 (ja) | 2015-06-25 | 2021-10-12 | キメラ抗体受容体（ＣＡＲｓ）の構成およびその使用方法 |
| JP2023053851A Active JP7502515B2 (ja) | 2015-06-25 | 2023-03-29 | キメラ抗体受容体（ＣＡＲｓ）の構成およびその使用方法 |
| JP2024092213A Pending JP2024116259A (ja) | 2015-06-25 | 2024-06-06 | キメラ抗体受容体（ＣＡＲｓ）の構成およびその使用方法 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US11655452B2 (https=) |
| EP (1) | EP3313872A4 (https=) |
| JP (4) | JP6961497B2 (https=) |
| KR (1) | KR20180021137A (https=) |
| CN (2) | CN107849112B (https=) |
| AU (3) | AU2016283102B2 (https=) |
| CA (2) | CA3287691A1 (https=) |
| IL (2) | IL287718B2 (https=) |
| SG (1) | SG10201913682QA (https=) |
| TW (2) | TWI833684B (https=) |
| WO (1) | WO2016210293A1 (https=) |
Families Citing this family (172)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2948544A4 (en) | 2013-01-28 | 2016-08-03 | St Jude Childrens Res Hospital | CHIMERIC RECEPTOR WITH NKG2D SPECIFICITY FOR CELL THERAPY AGAINST CANCER AND INFECTION DISEASES |
| AU2015259877B2 (en) | 2014-05-15 | 2021-02-25 | National University Of Singapore | Modified natural killer cells and uses thereof |
| KR102376244B1 (ko) | 2014-12-24 | 2022-03-21 | 오토러스 리미티드 | 세포 |
| MX2017012939A (es) | 2015-04-08 | 2018-05-22 | Novartis Ag | Terapias cd20, terapias cd22 y terapias de combinacion con una celula que expresa un receptor quimerico de antigeno (car) de cd19. |
| US11173179B2 (en) | 2015-06-25 | 2021-11-16 | Icell Gene Therapeutics Llc | Chimeric antigen receptor (CAR) targeting multiple antigens, compositions and methods of use thereof |
| US20220241327A1 (en) * | 2015-06-25 | 2022-08-04 | Icell Gene Therapeutics Llc | Chimeric Antigen Receptor (CAR) Targeting Multiple Antigens, Compositions and Methods of Use Thereof |
| TWI833684B (zh) * | 2015-06-25 | 2024-03-01 | 美商生物細胞基因治療有限公司 | 嵌合抗原受體（ｃａｒ）、組合物及其使用方法 |
| WO2017030370A1 (ko) | 2015-08-17 | 2017-02-23 | 서울대학교산학협력단 | 항-코티닌 항체가 연결된 키메라 항체 수용체 및 이의 용도 |
| EP3443001B1 (en) | 2016-04-11 | 2025-04-30 | Obsidian Therapeutics, Inc. | REGULATED BIOCIRCUIT SYSTEMS |
| US11293021B1 (en) | 2016-06-23 | 2022-04-05 | Inscripta, Inc. | Automated cell processing methods, modules, instruments, and systems |
| JP7114490B2 (ja) | 2016-06-24 | 2022-08-08 | アイセル・ジーン・セラピューティクス・エルエルシー | キメラ抗体受容体（ＣＡＲｓ）の構成およびその使用方法 |
| NZ750256A (en) | 2016-08-03 | 2026-02-27 | Dipersio John F | Gene editing of car-t cells for the treatment of t cell malignancies with chimeric antigen receptors |
| US11078481B1 (en) * | 2016-08-03 | 2021-08-03 | KSQ Therapeutics, Inc. | Methods for screening for cancer targets |
| EP4282969A3 (en) * | 2016-09-02 | 2024-01-31 | Lentigen Technology, Inc. | Compositions and methods for treating cancer with duocars |
| JP2019535262A (ja) * | 2016-11-11 | 2019-12-12 | オートラス リミテッド | キメラ抗原受容体 |
| US11851491B2 (en) * | 2016-11-22 | 2023-12-26 | TCR2 Therapeutics Inc. | Compositions and methods for TCR reprogramming using fusion proteins |
| EP3581190B1 (en) | 2016-12-09 | 2021-03-10 | ONK Therapeutics Limited | Engineered natural killer cells and uses thereof |
| JP7033601B2 (ja) | 2017-01-05 | 2022-03-10 | コリア リサーチ インスティチュート オブ バイオサイエンス アンド バイオテクノロジー | 抗コチニンキメラ抗原受容体を発現するナチュラルキラー細胞 |
| CN110582509A (zh) * | 2017-01-31 | 2019-12-17 | 诺华股份有限公司 | 使用具有多特异性的嵌合t细胞受体蛋白治疗癌症 |
| CA3051866A1 (en) * | 2017-02-01 | 2018-08-09 | Nant Holdings Ip, Llc | Calreticulin-mediated cancer treatment |
| EP3592137B1 (en) * | 2017-03-10 | 2024-08-07 | The Medical College of Wisconsin, Inc. | Riboswitch modulated gene therapy for retinal diseases |
| AU2018235756B2 (en) | 2017-03-13 | 2024-08-08 | Poseida Therapeutics, Inc. | Compositions and methods for selective elimination and replacement of hematopoietic stem cells |
| KR102660336B1 (ko) | 2017-03-27 | 2024-04-26 | 내셔널 유니버시티 오브 싱가포르 | 절단된 nkg2d 키메라 수용체 및 자연 살해 세포 면역요법에서의 그의 용도 |
| MX2019011570A (es) | 2017-03-27 | 2019-11-18 | Nat Univ Singapore | Lineas celulares estimuladoras para expansion y activacion ex vivo de celulas asesinas naturales. |
| EP3612568B8 (en) * | 2017-04-18 | 2021-12-08 | Autolus Limited | Cell |
| WO2018195339A1 (en) * | 2017-04-19 | 2018-10-25 | Board Of Regents, The University Of Texas System | Immune cells expressing engineered antigen receptors |
| WO2018201056A1 (en) | 2017-04-28 | 2018-11-01 | Novartis Ag | Cells expressing a bcma-targeting chimeric antigen receptor, and combination therapy with a gamma secretase inhibitor |
| EP3615068A1 (en) | 2017-04-28 | 2020-03-04 | Novartis AG | Bcma-targeting agent, and combination therapy with a gamma secretase inhibitor |
| AU2018269194B2 (en) * | 2017-05-15 | 2025-05-22 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Bicistronic chimeric antigen receptors and their uses |
| JP7317718B2 (ja) | 2017-06-02 | 2023-07-31 | ファイザー・インク | Ｆｌｔ３を標的にするキメラ抗原受容体 |
| CA3063169A1 (en) * | 2017-06-07 | 2018-12-13 | The General Hospital Corporation | T cells expressing a chimeric antigen receptor |
| SG11201912010XA (en) * | 2017-06-12 | 2020-01-30 | Obsidian Therapeutics Inc | Pde5 compositions and methods for immunotherapy |
| CA3287539A1 (en) * | 2017-06-21 | 2026-03-02 | Icell Gene Therapeutics Llc | CHIMERIC ANTIGEN RECEPTORS (CARs), COMPOSITIONS AND METHODS THEREOF |
| US10011849B1 (en) | 2017-06-23 | 2018-07-03 | Inscripta, Inc. | Nucleic acid-guided nucleases |
| US9982279B1 (en) | 2017-06-23 | 2018-05-29 | Inscripta, Inc. | Nucleic acid-guided nucleases |
| CA3068634A1 (en) | 2017-06-30 | 2019-01-03 | Memorial Sloan Kettering Cancer Center | Compositions and methods for adoptive cell therapy for cancer |
| CA3068641A1 (en) | 2017-06-30 | 2019-01-03 | Memorial Sloan Kettering Cancer Center | Compositions and methods for adoptive cell therapy |
| US12241097B2 (en) | 2017-06-30 | 2025-03-04 | Memorial Sloan Kettering Cancer Center | Compositions and methods for adoptive cell therapy for cancer |
| MX2019015505A (es) | 2017-06-30 | 2020-07-28 | Inscripta Inc | Metodos, modulos, instrumentos y sistemas de procesamiento de celulas automatizados. |
| US20210017247A1 (en) * | 2017-07-03 | 2021-01-21 | Torque Therapeutics, Inc. | Fusion Molecules Targeting Immune Regulatory Cells and Uses Thereof |
| WO2019018525A1 (en) * | 2017-07-20 | 2019-01-24 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | CHIMERIC ANTIGENIC RECEPTORS BINDING TO CD123 |
| US20200270574A1 (en) * | 2017-09-29 | 2020-08-27 | Nantcell, Inc. | CD1d and TCR-NKT Cells |
| US11905528B2 (en) | 2017-10-12 | 2024-02-20 | Icell Gene Therapeutics Inc. | Compound chimeric antigen receptor (cCAR) targeting multiple antigens, compositions and methods of use thereof |
| JP7585034B2 (ja) | 2017-10-18 | 2024-11-18 | ノバルティス アーゲー | 選択的タンパク質分解のための組成物及び方法 |
| JP7447006B2 (ja) | 2017-11-01 | 2024-03-11 | ジュノー セラピューティクス インコーポレイテッド | Ｂ細胞成熟抗原（ｂｃｍａ）に特異的なキメラ抗原受容体 |
| WO2019089813A1 (en) * | 2017-11-01 | 2019-05-09 | Nantkwest, Inc. | Nk-92 cells to stimulate anti-cancer vaccine |
| SG11202004512XA (en) | 2017-11-15 | 2020-06-29 | Novartis Ag | Bcma-targeting chimeric antigen receptor, cd19-targeting chimeric antigen receptor, and combination therapies |
| BR112020010579A2 (pt) | 2017-11-30 | 2020-11-10 | Novartis Ag | receptor de antígeno quimérico de alvejamento de bcma e usos do mesmo |
| EP3720882A4 (en) | 2017-12-05 | 2021-10-27 | The Medical Research, Infrastructure and Health Services Fund of the Tel Aviv Medical Center | T-CELLS WITH TWO DIFFERENT CHIMERIC ANTIGEN RECEPTORS AND THEIR USE |
| IL316570A (en) * | 2017-12-05 | 2024-12-01 | Medical Res Infrastructure & Health Services Fund Tel Aviv Medical Ct | T cells containing chimeric receptors for CD138 and CD38 antigens and their use |
| TW201930591A (zh) | 2018-01-08 | 2019-08-01 | 瑞士商諾華公司 | 用於與嵌合抗原受體療法併用之免疫增強rna |
| EP3746116A1 (en) | 2018-01-31 | 2020-12-09 | Novartis AG | Combination therapy using a chimeric antigen receptor |
| AU2019219454A1 (en) | 2018-02-09 | 2020-08-27 | National University Of Singapore | Activating chimeric receptors and uses thereof in natural killer cell immunotherapy |
| WO2019160956A1 (en) | 2018-02-13 | 2019-08-22 | Novartis Ag | Chimeric antigen receptor therapy in combination with il-15r and il15 |
| JP7273421B2 (ja) | 2018-02-21 | 2023-05-15 | ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム | ナチュラルキラー細胞の活性化および拡大のための方法ならびにその使用 |
| KR20200130324A (ko) | 2018-02-23 | 2020-11-18 | 에이치 리 모피트 캔서 센터 앤드 리서어치 인스티튜트 아이엔씨 | Cd83-결합 키메라 항원 수용체 |
| MX2020009272A (es) | 2018-03-06 | 2021-01-08 | Univ Pennsylvania | Receptores de antígeno quimérico del antígeno de membrana específico de próstata y métodos de uso de los mismos. |
| CN112055717B (zh) | 2018-04-02 | 2024-04-26 | 新加坡国立大学 | 用在免疫细胞中表达的膜结合抗细胞因子非信号传导粘合剂中和人细胞因子 |
| US20210145881A1 (en) * | 2018-04-09 | 2021-05-20 | Mayo Foundation For Medical Education And Research | Methods and materials for treating graft-versus-host disease |
| US10869888B2 (en) | 2018-04-17 | 2020-12-22 | Innovative Cellular Therapeutics CO., LTD. | Modified cell expansion and uses thereof |
| US10526598B2 (en) | 2018-04-24 | 2020-01-07 | Inscripta, Inc. | Methods for identifying T-cell receptor antigens |
| US10858761B2 (en) | 2018-04-24 | 2020-12-08 | Inscripta, Inc. | Nucleic acid-guided editing of exogenous polynucleotides in heterologous cells |
| EP3561053A1 (en) * | 2018-04-26 | 2019-10-30 | Baylor College of Medicine | Immune effector cells and molecular adaptors with an antigen cytokine complex for effective cancer immunotherapy |
| CA3098014A1 (en) * | 2018-04-27 | 2019-10-31 | Crispr Therapeutics Ag | Anti-bcma car-t-cells for plasma cell depletion |
| MX2020012927A (es) * | 2018-06-01 | 2021-03-25 | Univ Southern California | Diversos dominios de enlace de antigenos, nuevas plataformas y otras mejoras para terapia celular. |
| CN110577605A (zh) * | 2018-06-11 | 2019-12-17 | 浙江启新生物技术有限公司 | 一种靶向多发性骨髓瘤多种抗原的嵌合抗原受体t（car-t）细胞的构建方法及其应用 |
| AU2019292919A1 (en) | 2018-06-30 | 2021-03-11 | Inscripta, Inc. | Instruments, modules, and methods for improved detection of edited sequences in live cells |
| CN110305847B (zh) * | 2018-07-27 | 2021-05-18 | 赛诺生（深圳）基因产业发展有限公司 | 一种用于治疗肿瘤的基因工程细胞 |
| EP3830114A4 (en) * | 2018-07-31 | 2022-08-03 | Washington University | USE OF INTERLEUKIN-7 AND IMMUNE EFFECTIVE CELLS CARRIER OF THE CHIMERIC ANTIGEN RECEPTOR (CAR) TO TREAT A TUMOR |
| WO2020028656A1 (en) * | 2018-08-01 | 2020-02-06 | Nantkwest, Inc. | A quadricistronic system comprising a homing receptor or a cytokine, and chimeric antigen receptor for genetic modification of immunotherapies |
| WO2020033585A1 (en) * | 2018-08-07 | 2020-02-13 | The Broad Institute, Inc. | Methods for combinatorial screening and use of therapeutic targets thereof |
| GB201813178D0 (en) * | 2018-08-13 | 2018-09-26 | Autolus Ltd | Cell |
| US11142740B2 (en) | 2018-08-14 | 2021-10-12 | Inscripta, Inc. | Detection of nuclease edited sequences in automated modules and instruments |
| CN109306016B (zh) * | 2018-08-15 | 2021-10-22 | 华东师范大学 | 共表达细胞因子il-7的nkg2d-car-t细胞及其用途 |
| EP3844186A4 (en) | 2018-08-29 | 2022-08-17 | National University of Singapore | METHOD OF SPECIFIC STIMULATION OF SURVIVAL AND EXPANSION OF GENETICALLY MODIFIED IMMUNE CELLS |
| US12240915B2 (en) | 2018-08-30 | 2025-03-04 | Innovative Cellular Therapeutics Holdings, Ltd. | Chimeric antigen receptor cells for treating solid tumor |
| WO2020047449A2 (en) | 2018-08-31 | 2020-03-05 | Novartis Ag | Methods of making chimeric antigen receptor-expressing cells |
| CA3109959A1 (en) | 2018-08-31 | 2020-03-05 | Novartis Ag | Methods of making chimeric antigen receptor-expressing cells |
| CA3112584A1 (en) * | 2018-09-17 | 2020-03-26 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Bicistronic chimeric antigen receptors targeting cd19 and cd20 and their uses |
| WO2020061796A1 (en) * | 2018-09-26 | 2020-04-02 | Hrain Biotechnology Co., Ltd. | Bcma-and-cd19-targeting chimeric antigen receptor and uses thereof |
| US12331320B2 (en) | 2018-10-10 | 2025-06-17 | The Research Foundation For The State University Of New York | Genome edited cancer cell vaccines |
| WO2020077356A1 (en) * | 2018-10-12 | 2020-04-16 | Icell Gene Therapeutics Llc | CHIMERIC ANTIGEN RECEPTORS (CARs) COMPOSITIONS AND METHODS OF USE THEREOF |
| SG11202103317XA (en) * | 2018-10-17 | 2021-05-28 | Senti Biosciences Inc | Combinatorial cancer immunotherapy |
| US11214781B2 (en) | 2018-10-22 | 2022-01-04 | Inscripta, Inc. | Engineered enzyme |
| KR20240162586A (ko) | 2018-10-31 | 2024-11-15 | 난트퀘스트, 인크. | Pd-l1 키메라 항원 수용체-발현 nk 세포에 의한 pd-l1-양성 악성종양의 제거 |
| WO2020092736A1 (en) | 2018-10-31 | 2020-05-07 | Mayo Foundation For Medical Education And Research | Methods and materials for treating cancer |
| KR102665280B1 (ko) | 2018-10-31 | 2024-05-10 | 난트퀘스트, 인크. | Cd19-car 발현 nk 세포에 의한 cd19-양성 림프성 악성종양의 제거 |
| US12264189B2 (en) | 2018-10-31 | 2025-04-01 | Mayo Foundation For Medical Education And Research | Methods and materials for treating cancer |
| KR20210113169A (ko) | 2018-11-01 | 2021-09-15 | 주노 쎄러퓨티크스 인코퍼레이티드 | Β세포 성숙 항원에 특이적인 키메라 항원 수용체를 이용한 치료 방법 |
| EP3883955A1 (en) * | 2018-11-19 | 2021-09-29 | Board of Regents, The University of Texas System | A modular, polycistronic vector for car and tcr transduction |
| US10918667B2 (en) | 2018-11-20 | 2021-02-16 | Innovative Cellular Therapeutics CO., LTD. | Modified cell expressing therapeutic agent and uses thereof |
| US12590148B2 (en) | 2018-11-26 | 2026-03-31 | Nkarta, Inc. | Methods for the simultaneous expansion of multiple immune cell types, related compositions and uses of same in cancer immunotherapy |
| CN121518401A (zh) * | 2018-11-26 | 2026-02-13 | 免疫生物公司 | 具有稳定的Fc受体表达的IL-2依赖性NK-92细胞 |
| KR102840400B1 (ko) * | 2018-12-12 | 2025-08-04 | 카이트 파마 인코포레이티드 | 키메라 항원 수용체 및 car-t 세포 및 사용 방법 |
| US12600760B2 (en) | 2018-12-13 | 2026-04-14 | The General Hospital Corporation | Chimeric antigen receptors targeting CD79B and CD19 |
| EP3908613A4 (en) * | 2019-01-07 | 2022-10-19 | Celluris Participações Ltda. | BISPECIFIC IN-TANDEM RECEPTOR CAR AND METHODS FOR MODULATION OF THE TUMOR MICROAREA |
| CA3130489A1 (en) * | 2019-02-18 | 2020-08-27 | Memorial Sloan-Kettering Cancer Center | Combinations of multiple chimeric antigen receptors for immunotherapy |
| US20220152150A1 (en) | 2019-02-25 | 2022-05-19 | Novartis Ag | Mesoporous silica particles compositions for viral delivery |
| AU2020232691B2 (en) | 2019-03-05 | 2023-06-29 | Nkarta, Inc. | CD19-directed chimeric antigen receptors and uses thereof in immunotherapy |
| US12018061B2 (en) * | 2019-03-08 | 2024-06-25 | St Phi Therapeutics Co., Ltd. | Chimeric endocytic receptors and method of use thereof |
| US20220088073A1 (en) * | 2019-03-19 | 2022-03-24 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Chimeric antigen receptors with enhanced tumor infiltration |
| WO2020190902A1 (en) * | 2019-03-19 | 2020-09-24 | H. Lee Moffitt Cancer Center And Research Institute Inc. | Chimeric antigen receptors with enhanced tumor infiltration |
| EP3942025A1 (en) | 2019-03-21 | 2022-01-26 | Novartis AG | Car-t cell therapies with enhanced efficacy |
| CN113631713A (zh) | 2019-03-25 | 2021-11-09 | 因思科瑞普特公司 | 酵母中的同时多重基因组编辑 |
| US11001831B2 (en) | 2019-03-25 | 2021-05-11 | Inscripta, Inc. | Simultaneous multiplex genome editing in yeast |
| WO2020210678A1 (en) | 2019-04-12 | 2020-10-15 | Novartis Ag | Methods of making chimeric antigen receptor-expressing cells |
| US20220251152A1 (en) | 2019-04-24 | 2022-08-11 | Novartis Ag | Compositions and methods for selective protein degradation |
| CN114007626A (zh) * | 2019-04-26 | 2022-02-01 | 艾丽塔生物治疗剂公司 | 用于治疗癌症的组合物和方法 |
| EP3962527A4 (en) | 2019-04-30 | 2023-11-01 | Senti Biosciences, Inc. | CHIMERIC RECEPTORS AND METHODS OF USE THEREOF |
| US12023354B2 (en) * | 2019-05-31 | 2024-07-02 | Case Western Reserve University | Targeting B cell activating factor receptor (BAFF-R) using ligand-based chimeric antigen receptor (CAR)-T cells |
| AU2020288623A1 (en) | 2019-06-06 | 2022-01-06 | Inscripta, Inc. | Curing for recursive nucleic acid-guided cell editing |
| AU2020286471B2 (en) * | 2019-06-07 | 2025-07-31 | The Trustees Of The University Of Pennsylvania | Dual CAR expressing T cells individually linked to CD28 and 4-1BB |
| CA3148072A1 (en) * | 2019-07-19 | 2021-01-28 | Memorial Sloan-Kettering Cancer Center | Fusion polypeptide for immunotherapy |
| CN110452294B (zh) | 2019-08-06 | 2020-08-07 | 复旦大学 | 五种铰链区及其嵌合抗原受体和免疫细胞 |
| KR20220044534A (ko) * | 2019-08-13 | 2022-04-08 | 엘피스 바이오파마슈티컬즈 | 조작된 인터류킨-2 수용체 베타 효능제 |
| AU2020334317A1 (en) | 2019-08-16 | 2022-04-07 | Janssen Biotech, Inc. | Therapeutic immune cells with improved function and methods for making the same |
| JP7748935B2 (ja) * | 2019-08-27 | 2025-10-03 | ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア | ＩＬ１３Ｒα２陽性ヒト腫瘍およびイヌ腫瘍を処置するための合成ＣＡＲ |
| CN112442509A (zh) * | 2019-08-29 | 2021-03-05 | 爱博赛特生物治疗公司 | Cd19-cd20双特异性和双通道car-t及其使用方法 |
| CA3150224A1 (en) | 2019-09-10 | 2021-03-18 | Obsidian Therapeutics, Inc. | Ca2 compositions and methods for tunable regulation |
| US20220370500A1 (en) * | 2019-09-18 | 2022-11-24 | Board Of Regents, The University Of Texas System | A method of engineering natural killer-cells to target bcma-positive tumors |
| US11203762B2 (en) | 2019-11-19 | 2021-12-21 | Inscripta, Inc. | Methods for increasing observed editing in bacteria |
| IL292924A (en) | 2019-11-26 | 2022-07-01 | Novartis Ag | Chimeric antigen receptors cd19 and cd22 and their uses |
| PH12022551291A1 (en) | 2019-11-26 | 2023-11-20 | Novartis Ag | Chimeric antigen receptors binding bcma and cd19 and uses thereof |
| CA3160759A1 (en) * | 2019-12-05 | 2021-06-10 | Vycellix, Inc. | Modulators of the immune escape mechanism for universal cell therapy |
| EP4069851A4 (en) | 2019-12-18 | 2023-11-22 | Inscripta, Inc. | Cascade/dcas3 complementation assays for in vivo detection of nucleic acid-guided nuclease edited cells |
| WO2021146147A1 (en) * | 2020-01-13 | 2021-07-22 | Nkarta, Inc. | Bcma-directed cellular immunotherapy compositions and methods |
| CN115038453A (zh) * | 2020-01-14 | 2022-09-09 | 辛德凯因股份有限公司 | 具有改变的icd stat信号转导的cd122 |
| WO2021150970A1 (en) * | 2020-01-22 | 2021-07-29 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Bi-specific chimeric antigen receptor t cells targeting cd83 and interleukin 6 receptor |
| AU2021213705A1 (en) | 2020-01-27 | 2022-06-16 | Inscripta, Inc. | Electroporation modules and instrumentation |
| US11230699B2 (en) | 2020-01-28 | 2022-01-25 | Immunitybio, Inc. | Chimeric antigen receptor-modified NK-92 cells targeting EGFR super-family receptors |
| US20210238535A1 (en) * | 2020-02-02 | 2021-08-05 | Inscripta, Inc. | Automated production of car-expressing cells |
| AU2021217373A1 (en) * | 2020-02-05 | 2022-08-04 | Neoimmunetech, Inc. | Method of treating a solid tumor with a combination of an IL-7 protein and CAR-bearing immune cells |
| US12076343B2 (en) | 2020-02-19 | 2024-09-03 | Innovative Cellular Therapeutics Holdings, Ltd. | Engineered safety in cell therapy |
| KR20220146530A (ko) | 2020-02-27 | 2022-11-01 | 노파르티스 아게 | 키메라 항원 수용체-발현 세포의 제조 방법 |
| KR20220147109A (ko) | 2020-02-27 | 2022-11-02 | 노파르티스 아게 | 키메라 항원 수용체 발현 세포의 제조 방법 |
| IL296103A (en) | 2020-03-05 | 2022-11-01 | Neotx Therapeutics Ltd | Methods and compositions for treating cancer with immune cells |
| US20210332388A1 (en) | 2020-04-24 | 2021-10-28 | Inscripta, Inc. | Compositions, methods, modules and instruments for automated nucleic acid-guided nuclease editing in mammalian cells |
| CN115777017A (zh) * | 2020-05-06 | 2023-03-10 | 亘喜生物科技（上海）有限公司 | 用于t细胞工程改造的组合物及方法 |
| US20230227525A1 (en) * | 2020-05-08 | 2023-07-20 | Smt Bio Co., Ltd. | Chimeric antigen receptor for treatment of cancer |
| JP7748393B2 (ja) | 2020-05-08 | 2025-10-02 | アルパイン イミューン サイエンシズ インコーポレイテッド | Ａｐｒｉｌおよびｂａｆｆ阻害免疫調節タンパク質、ならびにその使用方法 |
| US11787841B2 (en) | 2020-05-19 | 2023-10-17 | Inscripta, Inc. | Rationally-designed mutations to the thrA gene for enhanced lysine production in E. coli |
| CA3180750A1 (en) * | 2020-05-29 | 2021-12-02 | Yupo Ma | Engineered immune cells, compositions and methods thereof |
| US12043654B2 (en) | 2020-06-02 | 2024-07-23 | Innovative Cellular Therapeutics Holdings, Ltd. | Anti-GCC antibody and CAR thereof for treating digestive system cancer |
| CN115867294A (zh) * | 2020-06-04 | 2023-03-28 | 凯瑞斯马治疗公司 | 嵌合抗原受体的新型构建体 |
| CA3185455A1 (en) | 2020-06-11 | 2021-12-16 | Novartis Ag | Zbtb32 inhibitors and uses thereof |
| US20230302155A1 (en) | 2020-08-21 | 2023-09-28 | Novartis Ag | Compositions and methods for in vivo generation of car expressing cells |
| GB202013477D0 (en) * | 2020-08-27 | 2020-10-14 | Quell Therapeutics Ltd | Nucleic acid constructs for expressing polypeptides in cells |
| WO2022052913A1 (en) * | 2020-09-08 | 2022-03-17 | Gracell Biotechnologies (Shanghai) Co., Ltd. | Compositions and methods for t cell engineering |
| WO2022060749A1 (en) | 2020-09-15 | 2022-03-24 | Inscripta, Inc. | Crispr editing to embed nucleic acid landing pads into genomes of live cells |
| WO2022076256A1 (en) * | 2020-10-05 | 2022-04-14 | Icell Gene Therapeutics Llc | Engineered immune cells for immunotherapy using endoplasmic retention techniques |
| WO2022086620A1 (en) | 2020-10-20 | 2022-04-28 | The Methodist Hospital System | Psma-targeted immunotherapies for cancers |
| US11512297B2 (en) | 2020-11-09 | 2022-11-29 | Inscripta, Inc. | Affinity tag for recombination protein recruitment |
| US20240000838A1 (en) * | 2020-11-30 | 2024-01-04 | Simcere Innovation, Inc. | Universal chimeric antigen receptor-expressing immune cells for allogeneic cell therapy |
| TW202233662A (zh) * | 2020-12-31 | 2022-09-01 | 大陸商亘喜生物科技（上海）有限公司 | 膜融合蛋白及其在免疫細胞中的應用 |
| AU2021415461A1 (en) | 2021-01-04 | 2023-08-17 | Inscripta, Inc. | Mad nucleases |
| US20240376451A1 (en) | 2021-01-07 | 2024-11-14 | Inscripta, Inc. | Mad nucleases |
| CN112778427B (zh) * | 2021-01-29 | 2022-03-15 | 武汉思安医疗技术有限公司 | 双特异性cs1-bcma car-t细胞及其应用 |
| US11884924B2 (en) | 2021-02-16 | 2024-01-30 | Inscripta, Inc. | Dual strand nucleic acid-guided nickase editing |
| CN112698037B (zh) * | 2021-03-25 | 2021-06-25 | 北京积水潭医院 | 一种检测多发性骨髓瘤治疗效果的抗体组合物及其试剂盒和应用 |
| EP4330381A1 (en) | 2021-04-27 | 2024-03-06 | Novartis AG | Viral vector production system |
| JP2024531364A (ja) | 2021-08-20 | 2024-08-29 | ノバルティス アーゲー | キメラ抗原受容体発現細胞を作製する方法 |
| US20250041339A1 (en) * | 2021-11-19 | 2025-02-06 | The Trustees Of The University Of Pennsylvania | Engineered Pan-Leukocyte Antigen CD45 to Facilityate CAR T Cell Therapy |
| CN114835820B (zh) * | 2022-04-14 | 2023-01-06 | 呈诺再生医学科技(珠海横琴新区)有限公司 | 用于基因改造的多能干细胞及、自然杀伤细胞的嵌合型Fc受体 |
| CN116574194A (zh) * | 2022-06-02 | 2023-08-11 | 深圳普瑞金生物药业股份有限公司 | 嵌合抗原受体及其用途 |
| CN115232217B (zh) * | 2022-07-04 | 2023-06-06 | 深圳市先康达生命科学有限公司 | 一种SynNotch结构及其应用 |
| GB202209920D0 (en) * | 2022-07-06 | 2022-08-17 | Autolus Ltd | Cell |
| CN120112650A (zh) | 2022-10-26 | 2025-06-06 | 诺华股份有限公司 | 慢病毒配制品 |
| KR102938028B1 (ko) * | 2022-11-11 | 2026-03-13 | 주식회사 유씨아이테라퓨틱스 | 유전자 조작된 세포 및 이의 용도 |
| KR102938027B1 (ko) * | 2022-11-11 | 2026-03-13 | 주식회사 유씨아이테라퓨틱스 | 유전자 조작된 세포 및 이의 용도 |
| WO2025059162A1 (en) | 2023-09-11 | 2025-03-20 | Dana-Farber Cancer Institute, Inc. | Car-engager containing il-2 variants to enhance the functionality of car t cells |
| EP4574838A1 (en) | 2023-12-21 | 2025-06-25 | Vilnius University | Chimeric antigen receptor (car) with enhanced recruitment of signaling partners |
| CN121488047A (zh) * | 2024-07-15 | 2026-02-06 | 南京元迈细胞生物科技有限公司 | 腺病毒载体及其应用 |
Family Cites Families (65)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6764681B2 (en) | 1991-10-07 | 2004-07-20 | Biogen, Inc. | Method of prophylaxis or treatment of antigen presenting cell driven skin conditions using inhibitors of the CD2/LFA-3 interaction |
| CA2386270A1 (en) | 1999-10-15 | 2001-04-26 | University Of Massachusetts | Rna interference pathway genes as tools for targeted genetic interference |
| US6326193B1 (en) | 1999-11-05 | 2001-12-04 | Cambria Biosciences, Llc | Insect control agent |
| AU2001275474A1 (en) | 2000-06-12 | 2001-12-24 | Akkadix Corporation | Materials and methods for the control of nematodes |
| US20030147865A1 (en) | 2002-02-07 | 2003-08-07 | Benoit Salomon | Cell therapy using immunoregulatory T-cells |
| US20080254027A1 (en) | 2002-03-01 | 2008-10-16 | Bernett Matthew J | Optimized CD5 antibodies and methods of using the same |
| WO2004022097A1 (en) | 2002-09-05 | 2004-03-18 | Medimmune, Inc. | Methods of preventing or treating cell malignancies by administering cd2 antagonists |
| US7435596B2 (en) | 2004-11-04 | 2008-10-14 | St. Jude Children's Research Hospital, Inc. | Modified cell line and method for expansion of NK cell |
| WO2005108415A2 (en) | 2004-04-30 | 2005-11-17 | Biogen Idec Ma Inc. | Membrane associated molecules |
| US20050277587A1 (en) | 2004-06-10 | 2005-12-15 | Academia Sinica | CD7 as biomarker and therapeutic target for psoriasis |
| EP1777294A1 (en) * | 2005-10-20 | 2007-04-25 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | IL-15Ralpha sushi domain as a selective and potent enhancer of IL-15 action through IL-15Rbeta/gamma, and hyperagonist (IL15Ralpha sushi -IL15) fusion proteins |
| CA2636424A1 (en) | 2006-01-09 | 2007-10-25 | The Regents Of The University Of California | Immunostimulatory combinations of tnfrsf, tlr, nlr, rhr, purinergic receptor, and cytokine receptor agonists for vaccines and tumor immunotherapy |
| MX2008015866A (es) | 2006-06-12 | 2009-01-14 | Centocor Inc | Metodo para detectar actividad de interleucina-16 y modulacion de la actividad de interleucina-16 con base en niveles proxi de celulas t normales expresadas y secretadas, reguladas sobre activacion. |
| CA2668208C (en) | 2006-11-02 | 2017-09-12 | Daniel J. Capon | Hybrid immunoglobulins with moving parts |
| WO2009091826A2 (en) | 2008-01-14 | 2009-07-23 | The Board Of Regents Of The University Of Texas System | Compositions and methods related to a human cd19-specific chimeric antigen receptor (h-car) |
| WO2010085660A2 (en) | 2009-01-23 | 2010-07-29 | Roger Williams Hospital | Viral vectors encoding multiple highly homologous non-viral polypeptides and the use of same |
| CA2761885A1 (en) | 2009-05-13 | 2010-11-18 | Genzyme Corporation | Methods and compositions for treating lupus |
| WO2010132697A2 (en) | 2009-05-13 | 2010-11-18 | Genzyme Corporation | Methods and compositions for treatment |
| EP2325322A1 (en) | 2009-11-23 | 2011-05-25 | 4-Antibody AG | Retroviral vector particles and methods for their generation and use |
| PH12013501201A1 (en) | 2010-12-09 | 2013-07-29 | Univ Pennsylvania | Use of chimeric antigen receptor-modified t cells to treat cancer |
| ES2791716T3 (es) | 2010-12-14 | 2020-11-05 | Univ Maryland | Células T que expresan al receptor de antígeno quimérico antietiqueta universal y métodos para el tratamiento del cáncer |
| EP2694080B1 (en) | 2011-04-06 | 2018-03-14 | SanBio, Inc. | Methods and compositions for modulating peripheral immune function |
| BR112014004168A2 (pt) | 2011-08-23 | 2017-12-12 | Roche Glycart Ag | anticorpo biespecífico, composição farmacêutica, uso do anticorpo biespecífico, célula hospedeira procariótica ou eucariótica, método de produção de anticorpo e invenção |
| JP6850528B2 (ja) * | 2012-02-13 | 2021-03-31 | シアトル チルドレンズ ホスピタル ドゥーイング ビジネス アズ シアトル チルドレンズ リサーチ インスティテュート | 二重特異性キメラ抗原受容体およびその治療的使用 |
| WO2013126712A1 (en) | 2012-02-22 | 2013-08-29 | The Trustees Of The University Of Pennsylvania | Compositions and methods for generating a persisting population of t cells useful for the treatment of cancer |
| TWI619729B (zh) | 2012-04-02 | 2018-04-01 | 再生元醫藥公司 | 抗－ｈｌａ－ｂ*２７抗體及其用途 |
| CN104507537A (zh) * | 2012-07-13 | 2015-04-08 | 宾夕法尼亚大学董事会 | 用于调节car t细胞的组合物和方法 |
| AU2013327136A1 (en) | 2012-10-02 | 2015-04-16 | Memorial Sloan-Kettering Cancer Center | Compositions and methods for immunotherapy |
| WO2014055657A1 (en) * | 2012-10-05 | 2014-04-10 | The Trustees Of The University Of Pennsylvania | Use of a trans-signaling approach in chimeric antigen receptors |
| AU2013204922B2 (en) | 2012-12-20 | 2015-05-14 | Celgene Corporation | Chimeric antigen receptors |
| SG11201507026WA (en) * | 2013-02-06 | 2015-10-29 | Anthrogenesis Corp | Modified t lymphocytes having improved specificity |
| EP4303232A3 (en) * | 2013-02-15 | 2024-04-17 | The Regents of The University of California | Chimeric antigen receptor and methods of use thereof |
| TW201446794A (zh) * | 2013-02-20 | 2014-12-16 | Novartis Ag | 利用抗－ｃｄ１２３嵌合抗原受體工程化ｔ細胞之初級人類白血病有效靶向 |
| EP2970426B1 (en) * | 2013-03-15 | 2019-08-28 | Michael C. Milone | Targeting cytotoxic cells with chimeric receptors for adoptive immunotherapy |
| PL3546572T3 (pl) | 2013-05-13 | 2024-07-22 | Cellectis | Chimeryczny receptor antygenowy swoisty względem cd19 i jego zastosowania |
| EP3783098A1 (en) * | 2013-05-14 | 2021-02-24 | Board Of Regents, The University Of Texas System | Human application of engineered chimeric antigen receptor (car) t-cells |
| KR102457731B1 (ko) | 2013-08-08 | 2022-10-21 | 싸이튠 파마 | 병용 약학 조성물 |
| MX389160B (es) | 2013-10-31 | 2025-03-20 | Hutchinson Fred Cancer Res | Células no t efectoras y madre/progenitoras hematopoyéticas modificadas y usos de estas. |
| CN110627907B (zh) | 2013-11-04 | 2024-03-29 | 艾科诺斯科技股份有限公司 | 重靶向t细胞的异源二聚免疫球蛋白的产生 |
| US20160296562A1 (en) | 2013-11-21 | 2016-10-13 | Ucl Business Plc | Cell |
| US11028143B2 (en) | 2014-01-21 | 2021-06-08 | Novartis Ag | Enhanced antigen presenting ability of RNA CAR T cells by co-introduction of costimulatory molecules |
| US20170145108A1 (en) | 2014-02-05 | 2017-05-25 | The University Of Chicago | Chimeric antigen receptors recognizing cancer-specific tn glycopeptide variants |
| ES3063961T3 (en) | 2014-02-14 | 2026-04-21 | Cellectis | Cells for immunotherapy engineered for targeting antigen present both on immune cells and pathological cells |
| CA2945320A1 (en) | 2014-04-10 | 2015-10-15 | Seattle Children's Hospital (dba Seattle Children's Research Institute) | Drug regulated transgene expression |
| DK3166968T3 (da) | 2014-05-02 | 2021-12-06 | Univ Pennsylvania | Sammensætninger og fremgangsmåder til kimæriske autoantistofreceptor-T-celler |
| JP6682509B2 (ja) | 2014-05-14 | 2020-04-15 | カースゲン セラピューティクス リミテッドＣａｒｓｇｅｎ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｌｉｍｉｔｅｄ | キメラ抗原受容体タンパク質をコードする核酸およびキメラ抗原受容体タンパク質を発現するｔリンパ球 |
| US11542488B2 (en) | 2014-07-21 | 2023-01-03 | Novartis Ag | Sortase synthesized chimeric antigen receptors |
| ES2791248T3 (es) * | 2014-08-19 | 2020-11-03 | Novartis Ag | Receptor antigénico quimérico (CAR) anti-CD123 para su uso en el tratamiento del cáncer |
| WO2016033331A1 (en) | 2014-08-28 | 2016-03-03 | Bioatla, Llc | Conditionally active chimeric antigen receptors for modified t-cells |
| JP2017531430A (ja) * | 2014-10-07 | 2017-10-26 | セレクティスＣｅｌｌｅｃｔｉｓ | Ｃａｒによって誘導される免疫細胞の活性を調節するための方法 |
| KR102376244B1 (ko) | 2014-12-24 | 2022-03-21 | 오토러스 리미티드 | 세포 |
| JP7237449B2 (ja) * | 2015-02-27 | 2023-03-13 | アイセル・ジーン・セラピューティクス・エルエルシー | 血液系腫瘍を標的としたキメラ抗体受容体（ＣＡＲｓ）の構成およびその使用方法 |
| MX2017012939A (es) * | 2015-04-08 | 2018-05-22 | Novartis Ag | Terapias cd20, terapias cd22 y terapias de combinacion con una celula que expresa un receptor quimerico de antigeno (car) de cd19. |
| TWI833684B (zh) * | 2015-06-25 | 2024-03-01 | 美商生物細胞基因治療有限公司 | 嵌合抗原受體（ｃａｒ）、組合物及其使用方法 |
| US11173179B2 (en) * | 2015-06-25 | 2021-11-16 | Icell Gene Therapeutics Llc | Chimeric antigen receptor (CAR) targeting multiple antigens, compositions and methods of use thereof |
| US20220241327A1 (en) * | 2015-06-25 | 2022-08-04 | Icell Gene Therapeutics Llc | Chimeric Antigen Receptor (CAR) Targeting Multiple Antigens, Compositions and Methods of Use Thereof |
| US20190135894A1 (en) * | 2015-06-25 | 2019-05-09 | iCell Gene Therapeuticics LLC | COMPOUND CHIMERIC ANTIGEN RECEPTOR (cCAR) TARGETING MULTIPLE ANTIGENS, COMPOSITIONS AND METHODS OF USE THEREOF |
| CN105087495B (zh) * | 2015-08-21 | 2016-04-27 | 深圳市茵冠生物科技有限公司 | 双嵌合抗原受体修饰的t淋巴细胞及其制备方法 |
| GB201518817D0 (en) | 2015-10-23 | 2015-12-09 | Autolus Ltd | Cell |
| WO2017112877A1 (en) * | 2015-12-22 | 2017-06-29 | Icell Gene Therapeutics, Llc | Chimeric antigen receptors and enhancement of anti-tumor activity |
| JP7114490B2 (ja) * | 2016-06-24 | 2022-08-08 | アイセル・ジーン・セラピューティクス・エルエルシー | キメラ抗体受容体（ＣＡＲｓ）の構成およびその使用方法 |
| EP4282877A3 (en) * | 2016-08-10 | 2024-02-21 | Legend Biotech Ireland Limited | Chimeric antigen receptors targeting bcma and methods of use thereof |
| CA3287539A1 (en) * | 2017-06-21 | 2026-03-02 | Icell Gene Therapeutics Llc | CHIMERIC ANTIGEN RECEPTORS (CARs), COMPOSITIONS AND METHODS THEREOF |
| US11905528B2 (en) * | 2017-10-12 | 2024-02-20 | Icell Gene Therapeutics Inc. | Compound chimeric antigen receptor (cCAR) targeting multiple antigens, compositions and methods of use thereof |
| BR112020010579A2 (pt) * | 2017-11-30 | 2020-11-10 | Novartis Ag | receptor de antígeno quimérico de alvejamento de bcma e usos do mesmo |
-
2016
- 2016-06-24 TW TW105120100A patent/TWI833684B/zh active
- 2016-06-24 CA CA3287691A patent/CA3287691A1/en active Pending
- 2016-06-24 TW TW113103577A patent/TW202444897A/zh unknown
- 2016-06-24 US US15/739,596 patent/US11655452B2/en active Active
- 2016-06-24 EP EP16815399.7A patent/EP3313872A4/en active Pending
- 2016-06-24 IL IL287718A patent/IL287718B2/en unknown
- 2016-06-24 CN CN201680036459.4A patent/CN107849112B/zh active Active
- 2016-06-24 SG SG10201913682QA patent/SG10201913682QA/en unknown
- 2016-06-24 WO PCT/US2016/039306 patent/WO2016210293A1/en not_active Ceased
- 2016-06-24 JP JP2017567178A patent/JP6961497B2/ja active Active
- 2016-06-24 CA CA2990177A patent/CA2990177C/en active Active
- 2016-06-24 CN CN202210523997.3A patent/CN115058395B/zh active Active
- 2016-06-24 AU AU2016283102A patent/AU2016283102B2/en active Active
- 2016-06-24 KR KR1020187002389A patent/KR20180021137A/ko active Pending
-
2017
- 2017-12-19 IL IL256410A patent/IL256410B/en unknown
-
2021
- 2021-05-28 AU AU2021203481A patent/AU2021203481B2/en active Active
- 2021-10-12 JP JP2021167360A patent/JP7254870B2/ja active Active
-
2023
- 2023-03-29 JP JP2023053851A patent/JP7502515B2/ja active Active
- 2023-09-22 AU AU2023233207A patent/AU2023233207B2/en active Active
-
2024
- 2024-06-06 JP JP2024092213A patent/JP2024116259A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018518974A5 (https=) | ||
| JP2019522973A5 (https=) | ||
| Klein et al. | Cergutuzumab amunaleukin (CEA-IL2v), a CEA-targeted IL-2 variant-based immunocytokine for combination cancer immunotherapy: Overcoming limitations of aldesleukin and conventional IL-2-based immunocytokines | |
| Verdon et al. | Cellular and molecular mechanisms of CD8+ T cell differentiation, dysfunction and exhaustion | |
| Sadelain | CAR therapy: the CD19 paradigm | |
| Li et al. | Increasing the safety and efficacy of chimeric antigen receptor T cell therapy | |
| Bayón-Calderón et al. | Facts and challenges in immunotherapy for T-cell acute lymphoblastic leukemia | |
| JP2024150546A (ja) | Ｃａｒ発現ベクター及びｃａｒ発現ｔ細胞 | |
| Birkholz et al. | Transfer of mRNA encoding recombinant immunoreceptors reprograms CD4+ and CD8+ T cells for use in the adoptive immunotherapy of cancer | |
| JP2020074776A5 (https=) | ||
| RU2015109631A (ru) | Способ и композиции для клеточной иммунотерапии | |
| JP2017513470A5 (https=) | ||
| RU2017121826A (ru) | Т-клетки, модифицированные химерным рецептором антигена, нацеленным на cs1 | |
| JP2017515464A5 (https=) | ||
| JP2020533301A5 (https=) | ||
| JP2020517259A5 (https=) | ||
| Opinto et al. | Hodgkin lymphoma: a special microenvironment | |
| RU2018118652A (ru) | Химерные конструкции антитело/т-клеточный рецептор и их применения | |
| RU2016143388A (ru) | Экспрессия трансгенов, регулируемая лекарственным средством | |
| RU2017121115A (ru) | Генетически модифицированные гамма дельта т-клетки | |
| RU2018105963A (ru) | Антитело против глипикана-3 и его применение | |
| RU2017111298A (ru) | Т-КЛЕТКИ С КОСТИМУЛИРУЮЩИМ ХИМЕРНЫМ АНТИГЕННЫМ РЕЦЕПТОРОМ, НАЦЕЛЕННЫЕ НА IL13Rα2 | |
| JP2021534740A5 (https=) | ||
| JP2016534717A5 (https=) | ||
| JP2016520074A5 (https=) |